- NEWS AND VIEWS
Reactivation of latent HIV moves shock-and-kill treatments forward
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 578, 42-43 (2020)
doi: https://doi.org/10.1038/d41586-020-00010-x
References
Finzi, D. et al. Nature Med. 5, 512–517 (1999).
Ruelas, D. S. & Greene, W. C. Cell 155, 519–529 (2013).
Nixon, C. C. et al. Nature 578, 160–165 (2020).
McBrien, J. B. et al. Nature 578, 154–159 (2020).
Cartwright, E. K. et al. Immunity 45, 656–668 (2016).
Jones, R. B. et al. PLoS Pathog. 12, e1005545 (2016).
Conlon, K. C. et al. J. Clin. Oncol. 33, 74–82 (2015).
Younes, S.-A. et al. J. Clin. Invest. 126, 2745–2756 (2016).
Okoye, A. et al. J. Exp. Med. 206, 1575–1588 (2009).
Spivak, A. M. & Planelles, V. Annu. Rev. Med. 69, 421–436 (2018).
Chen, H.-C., Martinez, J. P., Zorita, E., Meyerhans, A. & Filion, G. J. Nature Struct. Mol. Biol. 24, 47–54 (2017).
Cillo, A. R. et al. Proc. Natl Acad. Sci. USA 111, 7078–7083 (2014).
Ho, Y.-C. et al. Cell 155, 540–551 (2013).
Lee, G. Q. et al. J. Clin. Invest. 127, 2689–2696 (2017).